Optimal model establishment of whole-process management data for CAR-T therapy in China-how should this be done?
Cell Mol Immunol
.
2022 Jan;19(1):122-124.
doi: 10.1038/s41423-021-00789-3.
Epub 2021 Oct 25.
Authors
Xiaolei Li
1
2
,
Hanren Dai
2
,
Xian Li
3
,
Ping Li
4
,
Wenbin Qian
5
,
Aibin Liang
6
,
Weidong Han
7
Affiliations
1
Department of Bio-Therapeutics, the First Medical Centre, Chinese PLA General Hospital, Beijing, China.
2
Department of Oncology, the First Affiliated Hospital of Anhui Medical University, Hefei, China.
3
Department of Hematology, the Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
4
Department of Hematology, Tongji Hospital of Tongji University, Shanghai, China.
5
Department of Hematology, the Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China. qianwb@zju.edu.cn.
6
Department of Hematology, Tongji Hospital of Tongji University, Shanghai, China. lab7182@tongji.edu.cn.
7
Department of Bio-Therapeutics, the First Medical Centre, Chinese PLA General Hospital, Beijing, China. hanwdrsw69@yahoo.com.
PMID:
34697414
PMCID:
PMC8752796
DOI:
10.1038/s41423-021-00789-3
No abstract available
Publication types
Research Support, Non-U.S. Gov't
MeSH terms
China
Immunotherapy, Adoptive
Receptors, Chimeric Antigen*
Substances
Receptors, Chimeric Antigen
Grants and funding
31991171/National Natural Science Foundation of China (National Science Foundation of China)
81830002/National Natural Science Foundation of China (National Science Foundation of China)
31870873/National Natural Science Foundation of China (National Science Foundation of China)
81830006/National Natural Science Foundation of China (National Science Foundation of China)
81830004/National Natural Science Foundation of China (National Science Foundation of China)
2021M690184/China Postdoctoral Science Foundation
2021M690186/China Postdoctoral Science Foundation